The FemTech industry’s approach to PMOS, Pg7

Key Highlights:

• Polycystic Ovary Syndrome (PCOS) has been renamed Polyendocrine Metabolic Ovarian Syndrome (PMOS), a change published in The Lancet and led by Professor Helena Teede.
• The renaming acknowledges the multisystem nature of the condition, which includes endocrine, metabolic, reproductive, psychological, and dermatological symptoms.
• India's FemTech industry had already begun treating PCOS as a multisystem condition, offering integrated care packages.
• As of 2025, India’s FemTech market was estimated to be worth $1.48 billion.

PMOS.png

Detailed Insights:

• The rationale for renaming PCOS to PMOS was due to the original term's failure to capture the condition’s complexity, reducing it to a reproductive disorder.
• FemTech platforms in India provide integrated care packages, addressing gaps in conventional healthcare by including various specialists and focusing on long-term management.
• These platforms improve doctor-patient interactions by training gynaecologists to avoid prejudiced language and offering digital consultations for greater privacy.
• Reliance on FemTech creates vulnerabilities due to dependence on internet access, subscription costs, and investor confidence, disproportionately affecting urban, digitally savvy women.
• The long-term solution requires investment in public healthcare infrastructure and medical education, moving beyond a narrow, fertility-first framework.
• Broader environmental factors like adulterated food, pollution, chronic stress, and toxins should be considered in discussions around PMOS.

Key Concepts Involved:

• FemTech: Technology-based products and services focused on women's health.
• Integrated Care: A coordinated approach to healthcare involving multiple specialists.
• Public Health Infrastructure: The systems, resources, and facilities necessary for maintaining and improving population health.